Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database
Rayan Kaedbey, Christopher P Venner, Donna Reece, et al.
Blood Cancer Journal
|
September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Julie Côté, Richard LeBlanc, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Michael Wang, David Salek, David Belada, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Julia Varghese, Christopher P Venner, Martha Louzada, et al.
Cancer Medicine
|
November 5, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study
Mégane Tanguay, Jean Roy, Jiandong Su, et al.
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Leukemia & Lymphoma
|
May 3, 2022
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Deborah A Katz, Joan D Morris, Michael P Chu, et al.
The New England Journal of Medicine
|
January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Yael C Cohen, Hila Magen, Moshe Gatt, et al.
The Journal of Experimental Medicine
|
June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial
Matthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
The New England Journal of Medicine
|
December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database
Rayan Kaedbey, Christopher P Venner, Donna Reece, et al.
Blood Cancer Journal
|
September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Julie Côté, Richard LeBlanc, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Michael Wang, David Salek, David Belada, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Julia Varghese, Christopher P Venner, Martha Louzada, et al.
Cancer Medicine
|
November 5, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study
Mégane Tanguay, Jean Roy, Jiandong Su, et al.
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Leukemia & Lymphoma
|
May 3, 2022
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Deborah A Katz, Joan D Morris, Michael P Chu, et al.
The New England Journal of Medicine
|
January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Yael C Cohen, Hila Magen, Moshe Gatt, et al.
The Journal of Experimental Medicine
|
June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial
Matthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
The New England Journal of Medicine
|
December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
Page
of 5